Kindred Biosciences Inc (KIN:ASX) Investor Relations Material

Overview

Kindred Biosciences is a biopharmaceutical company that specializes in developing therapeutic treatments for pets. The company's product pipeline includes small molecules and biologics for a wide range of medical conditions in dogs, cats, and horses. Some of its products include Mirataz, a weight loss management ointment for cats, and Zimeta IV and Zimeta Oral, which help control fever in horses. Additionally, the company is working on developing monoclonal antibodies for various conditions such as atopic dermatitis, gastric ulcers, and inflammatory bowel disease in canines. Kindred Biosciences was founded in 2012 and is based in Burlingame, California.

Frequently Asked Questions

What is Kindred Biosciences Inc's ticker?

Kindred Biosciences Inc's ticker is KIN

What exchange is Kindred Biosciences Inc traded on?

The company's shares trade on the ASX stock exchange

Where are Kindred Biosciences Inc's headquarters?

They are based in Osborne Park, Australia

How many employees does Kindred Biosciences Inc have?

There are 11-50 employees working at Kindred Biosciences Inc

What is Kindred Biosciences Inc's website?

It is https://kindredbio.com/

What type of sector is Kindred Biosciences Inc?

Kindred Biosciences Inc is in the Basic Materials sector

What type of industry is Kindred Biosciences Inc?

Kindred Biosciences Inc is in the Gold industry

Who are Kindred Biosciences Inc's peers and competitors?

The following five companies are Kindred Biosciences Inc's industry peers:

- Predictive Discovery Limited

- Stoneridge

- Great Panther Mining

- Wheaton Precious Metals

- Cyprium Metals Limited